Brentford, United Kingdom
Brentford, United Kingdom

GlaxoSmithKline plc is a British multinational pharmaceutical, biologics, vaccines and consumer healthcare company which has its headquarters in Brentford, London. As of March 2014, it was the world's sixth-largest pharmaceutical company after Johnson & Johnson, Novartis, Hoffmann-La Roche, Pfizer, and Sanofi, measured by 2013 revenue. The company was established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham plc .The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of 2 May 2014 it had a market capitalisation of £79 billion, the fourth-largest of any company listed on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange. Andrew Witty has been the chief executive officer since May 2008.GSK manufactures drugs and vaccines for major disease areas such as asthma, cancer, infections, diabetes, digestive and mental health conditions, the biggest selling of which were Advair, Avodart, Flovent, Augmentin, Lovaza, and Lamictal in 2013. Many medicines were historically discovered or developed at GSK and its predecessor companies and are now sold as generics. Its drugs and vaccines earned £21.3 billion in 2013. Its consumer healthcare division, which earned £5.2 billion in 2013, sells oral healthcare and nutritional products, drinks and over-the-counter medicines, including Sensodyne, Boost and Horlicks.In July 2012 GSK pleaded guilty to criminal charges and agreed to a pay $3 billion to settle the criminal charges as well as civil qui tam lawsuits in the largest settlement paid by a drug company at the time. The criminal charges were for promoting Paxil and Wellbutrin for unapproved uses and failing to report safety data about Avandia; GSK paid $1 billion to settle the criminal charges. The remaining $2 billion were part of the civil settlement over unapproved promotion and paying kickbacks, making false statements concerning the safety of Avandia; and reporting false prices to Medicaid. GSK also signed an agreement which obligated it to make major changes to the way it did business.On December 17, 2013, GSK announced that it would stop paying professionals for speaking at medical conferences. The company stated that it would still pay fees to doctors for functions it regards as critical to obtaining insights into specific diseases, including performing company sponsored clinical trials, scientific advisory services, and market research.GlaxoSmithKline received top ranking among international pharmaceutical companies in the Access to Medicines Index in 2010, 2012 and 2014. In 2014 the company applied for regulatory approval for the first vaccine against malaria. The vaccine was developed as a joint project with the PATH vaccines initiative and the Bill and Melinda Gates Foundation. The company has committed to make the vaccine available in developing countries for a price set at 5% above the cost of production. Wikipedia.


Time filter

Source Type

Patent
Glaxosmithkline | Date: 2017-01-11

Nucleic acid immunisation is achieved by delivering a self-replicating RNA encapsulated within a small particle. The RNA encodes an immunogen of interest, and the particle may deliver this RNA by mimicking the delivery function of a natural RNA virus. Thus the invention provides a non-virion particle for in vivo delivery of RNA to a vertebrate cell, wherein the particle comprises a delivery material encapsulating a self-replicating RNA molecule which encodes an immunogen. These particles are useful as components in pharmaceutical compositions for immunising subjects against various diseases.


Patent
Glaxosmithkline | Date: 2017-03-08

The present invention relates to fusion proteins comprising fragments from toxin A and/or toxin B of Clostridium difficile, in particular the invention relates to proteins comprising a first fragment and a second fragment, wherein[0205] the first fragment is a toxin A repeating domain fragment;[0206] the second fragment is a toxin B repeating domain fragment;[0207] the first fragment has a first proximal end;[0208] the second fragment has a second proximal end; and wherein the first fragment and the second fragment are adjacent to one another and wherein the polypeptide elicits antibodies that neutralize toxin A or toxin B or both. The invention further relates to compositions comprising fragments or variants of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 or SEQ ID NO:34 or SEQ ID NO:35.


Patent
Glaxosmithkline | Date: 2017-03-15

The present application relates to immunogenic compositions comprising Type 5 and/or 8 capular polysaccharide or oligosaccharide from S. aureus having between 30-100% O-acetylation. Vaccines, methods of treatment using and processes to make an immunogenic composition comprising Type 5 and/or 8 capsular polysaccharides with 30-100% O-acetylation are also described.


Patent
Glaxosmithkline | Date: 2017-02-15

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.


Patent
Glaxosmithkline | Date: 2017-01-25

A combination comprising a compound of Formula (I):and one or more other therapeutic agents, selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotension II receptor antagonists, vasopeptidase inhibitors, vasopressin receptor modulators, diuretics, digoxin, beta blocker, aldosterone antagonists, iontropes, NSAIDS, nitric oxide donors, calcium channel modulators, muscarinic antagonists, steroidal anti-inflammatory drugs, bronchodilators, anti-histamines, leukotriene antagonist, HMG-CoA reductase inhibitors, dual non-selective -adrenoceptor and _(1)-adrenoceptor antagonists, type-5 phosphodiesterase inhibitors, and renin inhibitors.


Patent
Glaxosmithkline | Date: 2017-04-05

The present invention relates to pharmaceutical products comprising fluticasone furoate for use in the treatment of COPD patients, particularly a subgroup of COPD patients that through analysis have been identified as possessing an eosinophil blood count of 150 cells/l. The present invention is further directed to methods for treating a patient with COPD which methodsinclude identifying a patient that will respond to treatment and administering a pharmaceutical product of the present invention comprising fluticasone furoate to said patient.


Patent
Glaxosmithkline | Date: 2017-04-05

The present invention relates to novel retinoid-related orphan receptor gamma (ROR) modulators and their use in the treatment of diseases mediated by ROR.


Patent
Glaxosmithkline | Date: 2017-01-18

The invention is directed to substituted pyrrolidinone derivatives. Specifically, the invention is directed to compounds according to Formula X: wherein R41, R42, R43, R44, R45, R46, and R47 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer and diseases associated with activated unfolded protein response pathways, such as Alzheimers disease, stroke, diabetes, Parkinson disease, Huntingtons disease, Creutzfeldt- Jakob Disease, and related prion diseases, amyotrophic lateral sclerosis, myocardial infarction, neurodegeneration, cardiovascular disease, atherosclerosis, ocular diseases, and arrhythmias, more specifically cancers of the breast, colon, pancreas and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.


Patent
Glaxosmithkline and Northwestern University | Date: 2017-01-25

Disclosed are methods for treating cancer such as a myeloid malignancy such as multiple myeloma in a human using EZH2 inhibitors in human populations having a translocation MMSET or a decreased level of a functional UTX protein or both.

Loading Glaxosmithkline collaborators
Loading Glaxosmithkline collaborators